Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

SCHOTT Pharma AG & Co. KGaA (1SXP.F)

Compare
22.70
+0.05
+(0.22%)
As of 8:12:55 AM GMT+2. Market Open.
Loading Chart for 1SXP.F
  • Previous Close 22.65
  • Open 22.70
  • Bid --
  • Ask --
  • Day's Range 22.70 - 22.70
  • 52 Week Range 19.82 - 40.10
  • Volume 85
  • Avg. Volume 264
  • Market Cap (intraday) 3.419B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 25.51
  • EPS (TTM) 0.89
  • Earnings Date May 15, 2025
  • Forward Dividend & Yield 0.16 (0.71%)
  • Ex-Dividend Date Feb 5, 2025
  • 1y Target Est 28.53

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container. It also provides products comprising cartriQ, a pharmaceutical glass cartridge for peptide and protein-based injectables; cartriQ Large Volume, a pharmaceutical glass cartridge for large-volume injectables; Cartridges Double Chamber, a pharmaceutical glass cartridge for lyophilized drugs; Cartridges Break Resistant, a pharmaceutical glass cartridge; and TopLine and StandardLine cartridges. In addition, the company offers adaptiQ, a pharmaceutical glass vial for injectables; EVERIC pure, a pharmaceutical glass vial for unmatched drug stability; EVERIC care, a pharmaceutical glass vial for a pH range; EVERIC strong & smooth, a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for lyophilized drugs; and TopLine and StandardLine vials. Further, it provides ampoule products comprise Ampoules easyOPC, a pharmaceutical glass ampoule for ampoule opening; Ampoules Anti-Counterfeiting, a pharmaceutical glass ampoule for protection against drug counterfeiting; and StandardLine ampoules. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

www.schott-pharma.com

4,749

Full Time Employees

September 30

Fiscal Year Ends

Recent News: 1SXP.F

View More

Performance Overview: 1SXP.F

Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

1SXP.F
8.20%
DAX P (^GDAXI)
6.16%

1-Year Return

1SXP.F
39.53%
DAX P (^GDAXI)
18.96%

3-Year Return

1SXP.F
24.33%
DAX P (^GDAXI)
49.22%

5-Year Return

1SXP.F
24.33%
DAX P (^GDAXI)
105.17%

Compare To: 1SXP.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1SXP.F

View More

Valuation Measures

Annual
As of 4/15/2025
  • Market Cap

    3.40B

  • Enterprise Value

    3.46B

  • Trailing P/E

    25.45

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.57

  • Price/Book (mrq)

    4.11

  • Enterprise Value/Revenue

    3.63

  • Enterprise Value/EBITDA

    13.92

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.05%

  • Return on Assets (ttm)

    8.29%

  • Return on Equity (ttm)

    17.36%

  • Revenue (ttm)

    954.68M

  • Net Income Avi to Common (ttm)

    134.17M

  • Diluted EPS (ttm)

    0.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.78M

  • Total Debt/Equity (mrq)

    37.34%

  • Levered Free Cash Flow (ttm)

    -97.54M

Research Analysis: 1SXP.F

View More

Company Insights: 1SXP.F

Research Reports: 1SXP.F

View More

People Also Watch